Guardant Health, Inc.

NASDAQ:GH

Medical - Diagnostics & Research

Healthcare
$145.14 +2.07%

+$2.67 today

Market cap
$19.64B
Beta
1.62
P/E (TTM)
-39.9
EPS (TTM)
-$3.30
52W Low $40.35High $135.00

Volume 1.50M

Average 2.21M

GH Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Guardant Health, Inc.NASDAQ: GH

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income growth accelerates

Q3 FY2026 net income of $124.36M (cash outflow) rose 34.1% year over year, ahead of the +21.6% change in trailing-twelve-month net income. Sequentially, it rose 3.5% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.

Context

  • Net income amounted to 42.4% of revenue in FY2025, down 16.7 pp from a year earlier.
  • Net income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 19 analysts of -$429.41M (+3.2%) for the fiscal year ending Dec 2026, a step up from the -4.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$124.36M+3.5% QoQ
Last fiscal yearDec 2025
-$416.28M-4.6% YoY
LTMSep 2026
-$485.07M+21.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.1%-21.7%-55.8 pp
1 year-4.6%+3.2%+7.8 pp
3-year CAGR-14.0%-39.2%-25.2 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(416.28M) USD
Year-over-year change
+4.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GH compares with its peers on the latest reported figures

  • GH's LTM Sep 2026 net income of $485.07M is the largest of the 10 companies compared; the peer median is $74.56M.
  • Its year-over-year change of +21.6% is the 4th highest of 9, against a peer median of +1.0%.
  • Net income amounts to 37.9% of revenue for GH, versus a peer median of 23.3%.
GH Competitors Peer median
Net Income for GH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$485.07M +21.6%-14.0%37.9%
MYGNMyriad Genetics, Inc.LTM Mar 2026$399.9M +294.4%+48.4%48.2%
GRALGRAIL, Inc.LTM Jun 2026$391.59M -11.6%-57.7%236.9%
NTRANatera, Inc.LTM Jun 2026$192.35M -24.0%-27.6%7.1%
PSNLPersonalis, Inc.LTM Mar 2026$95.55M +13.7%-10.5%148.1%
FLGTFulgent Genetics, Inc.LTM Mar 2026$74.56M +78.1%—23.3%
NEONeoGenomics, Inc.LTM Jun 2026$51.88M -50.1%-9.2%6.8%
BLLNBillionToOne, Inc.LTM Jun 2026$37.71M ——9.5%
BDSXBiodesix, Inc.LTM Mar 2026$31.96M -20.9%-18.6%33.3%
CSTLCastle Biosciences, Inc.LTM Mar 2026$12.83M +153.1%-28.9%3.8%
Peer median (excluding GH) $74.56M+1.0%-18.6%23.3%

Competitors are the stored peer set for GH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(384.77M)(654.59M)(479.45M)(436.37M)(416.28M)
Depreciation & Amortization22.27M35.96M42.88M42.39M39.74M
Deferred Income Tax00000
Stock-Based Compensation151.45M94.69M90.76M140.41M166.22M
Change in Working Capital(40.47M)61.56M53.84M(60.86M)(14.43M)
Accounts Receivables(44.35M)375K8.38M(21.39M)(28.18M)
Inventory(7.96M)(20.93M)(10.35M)(9.14M)(14.79M)
Accounts Payables8.64M60.33M000
Other Working Capital3.2M21.79M55.81M(30.34M)28.54M
Other Non-Cash Items42.5M152.91M(33.01M)74.58M39.99M
Operating Cash Flow(209.02M)(309.46M)(324.98M)(239.86M)(184.76M)
Capital Expenditures(75.04M)(77.46M)(20.49M)(35.09M)(48.31M)
Acquisitions (Net)0000(58.99M)
Purchases of Investments(940.23M)(327.72M)(635.5M)(314.82M)(827.23M)
Sales of Investments952.11M555M1.5B88.6M307.32M
Other Investing Activities00000
Investing Cash Flow(63.16M)149.82M840.25M(261.31M)(627.2M)
Debt Repayment(146K)(71K)00402.5M
Common Stock Issued00493.12M14.84M377.81M
Common Stock Repurchased0000(45.01M)
Dividends Paid00000
Other Financing Activities(66.68M)(189.02M)(15.74M)(15.83M)(64.17M)
Financing Cash Flow(66.82M)(189.09M)477.38M(996K)671.13M
Effect of Forex Changes(1.69M)(1.6M)(911K)(1.77M)491K
Net Change in Cash(340.69M)(350.34M)991.74M(503.93M)(140.34M)
Free Cash Flow(284.05M)(386.92M)(345.46M)(274.94M)(233.07M)

Guardant Health, Inc.

NASDAQ:GH

Intrinsic Alpha fair value

Locked

Current Price

$145.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.